Posted by zeugma on March 5, 2005, at 20:03:57
In reply to My little theory on reboxetine.Therapeutic window?, posted by ed_uk on March 5, 2005, at 14:27:21
Hi Ed.
Atomoxetine is believed to have a therapeutic window for the treatment of ADD.
interestingly, no such windows exist for dopaminergic treatments for ADD, hence dosing is far more empirical (as a matter of fact, it appears to be polymorphisms of the dopamine transporter gene and the D4 receptor that determine dose-response to stimulants, rather than polymorphisms of CYP enzymes).
Reboxetine antagonizes nicotinic receptors in a manner similar to bupropion, which could mean that reboxetine, like bupropion and nortriptyline, is an effective treatment for smoking cessation.
I wonder why nortriptyline has a clear therapeutic window, while its cousin desipramine does not?
And atomoxetine caused a horrible dysphoria the last few times I've tried it. Another coincidence?
-z
poster:zeugma
thread:467005
URL: http://www.dr-bob.org/babble/20050304/msgs/467134.html